The purpose of the study is to substantiate the use of narrow-band optical radiation with an average wavelength of 470 nm (blue light) as a part of the comprehensive therapy of COVID-19. Materials and methods. 29 patients with COVID-19 were examined. All the patients were randomly divided into 2 clinically comparable groups: the main group (16 patients), in parallel with the drug therapy, received 10 sessions of narrow-band optical radiation with an average wavelength of 470 nm using the laser-LED therapeutic system «Spectrum-LC»; the control group (13 patients) received drug therapy in accordance with the scheme of the interim guidelines for the prevention, diagnosis, and treatment of the novel coronavirus infection COVID-19. The unified examination algorithm included the analysis of medical histories, anamnesis of the disease, concomitant somatic pathology, and allergic reactions. The following laboratory methods were used: complete blood count, biochemical blood test, coagulogram parameters (fibrinogen, D-dimer, Quick prothrombin time, activated partial thromboplastin time), polymerase chain reaction; the instrumental examination methods were as follows: pulse oximetry, electrocardiography, and multispiral computed tomography of the chest. After the comprehensive therapy with the blue light, the following results were noted: a significant decrease in the severity of the pathological process based on the results of computed tomography of the lungs — a decrease in the volume of lung tissue damage by 9 %, relief of intoxication, neurotic, and astheno-depressive syndromes on the 10th day of inpatient treatment, stabilization of the general condition on the 8th-10th day of inpatient therapy, reduction of hospitalization time to 13–14 days, positive changes of laboratory parameters: a significant decrease in the neutrophil parameter by 26.35 %, in the CRP parameter by 89.24 mg/l, in the fibrinogen parameter by 2.75 g/l, and in AST parameter by 61.27 units/l.